guanosine monophosphate-specific, rod, beta (PDE6B, underlying nonsyndromic RP) [7] .
METHODS

Subjects:
Family members were recruited following approval by the National Helsinki Committee for Genetic Research in Humans (Jerusalem) and by the local institutional review board at Rambam Medical Center in Haifa. Written informed consent was obtained from all participants or their parents. Patients underwent a detailed ophthalmic examination, including best visual correction, color vision, confrontational visual field, pupil response to light, funduscopy and fundus photographs, electroretinography (ERG), and optical coherence tomography (OCT).
DNA analysis: Venous blood samples were obtained using K3EDTA vacuette tubes (Greiner Bio-One, Kremsmunster, Austria), and genomic DNA was extracted using high salt solution according to a standard protocol [8] . Genome-wide homozygosity mapping was performed using the HumanCytoSNP-12v2.1 BeadChip (220 K; Illumina, San Diego, CA). Homozygous regions were calculated using HomozygosityMapper [9] . Whole exome sequencing (WES) was performed at Otogenetics Corporation (Norcross, GA) using a Roche NimbleGen (Madison, WI) V2 (44.1 Mbp) pairedend sample preparation kit and Illumina HiSeq2000. A total of 5.1 gigabases (Gb) of paired-end 100-nucleotide sequence reads were obtained for each sample, 90% of which were mapped to gene regions following alignment to the human genome reference sequence (hg19) using the DNAnexus software package. Average exome coverage was 45 reads per nucleotide (coverage range 4-10,000). Variants were called and annotated according to the dbSNP database (build 129) using the DNAnexus software package.
For mutation confirmation and segregation analysis, specific primers were used to PCR amplify MY07A exon 20 (5ʹ-TCC TGA TCC CAA ACC CAC-3ʹ and 5ʹ-TGC CAT GGC AGC AAG GCT-3ʹ) and PDE6B exon 11 (5ʹ-ACG GTC ATT TGT CTC CAG AT-3ʹ and 5ʹ-AGT CAG GCC CAC TAA ACA TC-3ʹ). Mutation screening was performed with direct sequencing with the Big Dye terminator cycle sequencing kit on an ABI 3130×l Genetic Analyzer (PE Applied Biosystems, Foster City, CA).
RESULTS
Family TB128 is an Israeli Muslim Arab family. The parents are first cousins. Three of their four offspring ( Figure 1A , individuals II:1, II:3, and II:4) were diagnosed with RP at the ages of 10 years, 7 years, and 9 months, respectively. Individual II:3 has normal hearing and motor development, while individuals II:1 and II:4 have bilateral profound SNHL, which was detected in infancy. They received cochlear implants at the ages of 3 years and 9 months, respectively. Both manifested a delay in motor development and walked independently only at 20-24 months of age. The combination of RP, congenital profound SNHL, and vestibular dysfunction is consistent with a diagnosis of USH1 [3] . A fourth sibling has normal hearing and vision.
Initially, the gene encoding connexin 26 (the most common cause of hereditary HL worldwide) [10] of individual II:1was sequenced, and her DNA was screened for known USH mutations using the Asper microarray system [11] . Both tests were negative.
When affected siblings are the outcome of a consanguineous marriage, the assumption is that their disease is due to homozygosity for the same recessive mutant allele. However, it is hard to explain the existence of USH1 and nonsyndromic RP in three siblings by a single mutation. To date, the only USH gene associated with nonsyndromic RP is USH2A, underlying USH2 (in which HL is not profound and vestibular function is usually normal) [3, 12] . In USH3, there may be intrafamilial variability regarding the age of onset of HL; however, it is usually post-lingual and progressive [13, 14] . Mutations of USH1 genes have not been associated with nonsyndromic RP, and partial penetrance has not been reported [3] . One exception is a recently identified mutation of USH1C, which causes RP associated with late-onset and relatively mild HL. These patients might be initially diagnosed with nonsyndromic RP [15] . Based on these facts, our working hypothesis was that family TB128 might segregate recessive mutations of two different genes, independently causing RP and HL, and mimicking the USH1 phenotype. Similar cases have been previously reported [16] .
To identify these genes, we performed genome-wide homozygosity mapping using DNA samples from the three RP-affected individuals. One of the homozygous intervals shared among these three individuals included a known RP-causative gene (nuclear receptor subfamily 2, group E, member 3; NR2E3); however, screening of all coding exons was negative for mutations. We then looked for homozygous intervals shared between the two deaf individuals only. We found a 44 Mb interval on chromosome 11 that included the MYO7A gene, underlying USH1B [6] . We next performed WES on DNA samples from individuals II:1 (HL and RP) and II:3 (RP only). A homozygous deletion of a C nucleotide at position 2308 of MYO7A cDNA (GenBank accession number NM_000260), located in exon 20 (c.2308delC), was identified in individual II:1 ( Figure 1B ). This novel mutation is expected to lead to a frameshift and premature termination of translation after insertion of four irrelevant amino acids, starting at position 769 of the myosin VIIA protein (p.N769fsX4). Individual II:3 was heterozygous for this mutation, and no other MYO7A mutation was detected.
The homozygosity data for individual II:3 showed multiple homozygous intervals, which included three known retinal degeneration-causative genes: IQ motif containing B1 (IQCB1), rhodopsin (RHO), and PDE6B. WES data revealed a deletion of a C nucleotide at position 1417 of PDE6B cDNA (GenBank accession number NM_000283), located in exon 11 (c.1417delC; Figure 1B ). This novel mutation is expected to lead to a frameshift and premature termination of translation after insertion of 16 irrelevant amino acids, starting at position 473 of the PDE6B protein (p.L473fsX16). This mutation was found homozygously in individual II:3 and was not detected in individual II:1. Both mutations were confirmed with direct Sanger sequencing. Segregation analysis in the family revealed that parents were heterozygotes for both mutations, while the unaffected sister was heterozygote for the PDE6B mutation only. Interestingly, the third affected brother (individual II:4) was homozygous for both mutations ( Figure 1A ).
Ophthalmologic evaluation was performed in all family members. Clinical findings are summarized in Table 1 . Both parents had normal vision with no pathological findings. Individual II:3 (PDE6B mutation homozygote) was first diagnosed with RP at the age of 7 years. At this age, the cone and rod ERG responses were recordable, but reduced, with the rods more severely affected (Table 1) . At the age of 13 years, he had constricted visual fields, waxy pallor of the optic discs, severe attenuation of retinal blood vessels, and severe bone spicule-like pigmentation in the entire periphery ( Figure 2C ). His older sister (II:1, MYO7A homozygote) had a milder retinal phenotype. At the age of 12 years, the cone and rod ERG responses were recordable, but reduced, with the rods more severely affected (Table 1) . At the age of 15 years, her visual fields were normal, and the degenerative changes observed in her retina were relatively mild with mild attenuation of the arteries (Figure 2A,B) . OCT imaging in II:1 and II:3 showed normal macular thickness ( Figure 2E-H) . The youngest sibling (individual II:4) is homozygote for PDE6B and MYO7A mutations. His retinal dysfunction was diagnosed as early as 9 months of age, based on severely reduced ERG responses measured using a short protocol (without full dark adaptation; Table 1 ). At the age of 32 months, his confrontational visual field appeared normal, and he had mild attenuation of retinal blood vessels, with no overt pigmentary changes ( Figure 2D ). Full-field ERG rod responses recorded at 3 years of age following 40 min of dark adaptation were non-detectable, and the mixed cone-rod response was severely attenuated. Cone responses were similarly severely reduced and delayed (Table 1) . Notably, his brother (II:3), who is homozygous for the PDE6B mutation only, had better conserved cone ERG responses at the older age of 7 years. His rod responses were similarly non-detectable, and mixed cone-rod responses also severely reduced ( Table 1) . The oldest sister (II:1), who is homozygous for the MYO7A mutation only, had lower mixed cone-rod and cone ERG responses at the age of 12 years (Table 1) .
DISCUSSION
HRD is a strikingly heterogeneous condition, associated with mutations in more than 100 genes and loci (RetNet) [1] . The contribution of each one of these genes to the overall prevalence of retinal degeneration is relatively small. However, the total number of pathogenic mutations in all HRD-causative genes is relatively elevated in the general population, and it is estimated that approximately 1 in 4-5 individuals may be a carrier of null mutations responsible for HRD. Due to the highly heterogenous nature of HRD, such an elevated frequency of unaffected carriers has a limited influence on the likelihood of generating affected offspring, since the chance of two unrelated parents carrying each a heterozygous mutation in the same gene remains low. However, the risk for consanguineous couples of generating a child with HRD is particularly high, compared to other genetic conditions [17] . Here, we present a rare case of three siblings with the same retinal phenotype (RP) and three different genotypes (MYO7A deficiency, PDE6B deficiency, or both).
In the retina, most myosin VIIA is localized in retinal pigmented epithelial (RPE) cells, where the protein is involved in organelle motility and in light-dependent translocation of the visual cycle enzyme RPE65. A small amount of myosin VIIA is also associated with the connecting cilium of photoreceptor cells, where it may be involved in maintaining a diffusion barrier (reviewed in [18] ).
PDE6B encodes the β subunit of rod photoreceptor cyclic guanosine monophosphate (cGMP)-phosphodiesterase (PDE), a key enzyme of the visual phototransduction cascade. The holoenzyme is a heterotetrameric complex, consisting of α, β, and two identical γ subunits. Activation of cGMP-PDE leads to reduced intracellular concentration of cGMP, thus closing cGMP-gated cation channels located on the rod plasma membrane and initiating a neural response to light [19] . Malfunctioning of cGMP-PDE results in elevated cGMP concentrations, which may lead to an excessive energy load on rod photoreceptors, resulting in degeneration [20] . Indeed, mutations in the genes encoding each of the subunits α, β, and γ, cause arRP [7, 21, 22] .
The mutations we identified in MYO7A and PDE6B are truncating and consequently expected to be null. The retinal phenotypes observed in individuals II:1 and II:3 are consistent with those previously reported in other patients with mutations in MYO7A and PDE6B, respectively [6, 7] . The retinal phenotype seen in patient II:4, who is homozygous for mutations in both genes, results from overlapping pathologies that include a combination of cellular defects affecting RPE function, visual cycle, and photoreceptor cell structure and survival. An intriguing question is whether this "double hit" translates into more severe manifestation of the retinal disease. The young age at which this child was diagnosed with RP (9 months) could suggest increased severity, but it may simply reflect increased awareness of the parents and treating physicians following the presence of disease in two of his older siblings and the profound deafness that was apparent early on. ERG testing performed in this child at the age of 3 years, as detailed above, may suggest a somewhat more severe degenerative process at least as compared with the brother manifesting RP due to the homozygous PDE6B mutation, who had a better preserved cone function at the older age of 7 years. However, further testing of visual function and structure over time in the three siblings is needed to determine whether the fact that two RP-causing genes are mutated in this youngest sibling confers increased disease severity. Interestingly, a patient homozygous for mutations of PDE6B and G protein-coupled receptor 98 (GPR98), the gene underlying USH2C, has been previously reported. Her retinal phenotype was indeed more severe than that of her affected relatives who were homozygous for mutations in either of these two genes [5] . The current report reinforces the genetic heterogeneity of RP, and demonstrates how consanguinity could increase intrafamilial clustering of multiple hereditary diseases. Moreover, this report provides a unique opportunity to study the clinical implications of the coexistence of null mutations in two RP-causative genes in a human patient.
